Our Partnerships and Collaborations
By balancing our internal research and product development with academic collaboration and corporate partnering, we have the opportunity to advance our PLE delivery platform and our promising pipeline of oncology product candidates.
We have entered into a research collaboration with Pierre Fabre, the third largest French pharmaceutical company, which is designed to combine our proprietary PLE delivery platform with a selection of Pierre Fabre's proprietary cytotoxics. These new PDCs are designed to exhibit high selectivity towards various solid tumors. The primary goal is to improve the therapeutic index and provide the potential for improved clinical performance to these otherwise highly potent agents.
We are collaborating with Avicenna Oncology GmbH, a leading antibody drug conjugate development company based in Basel, Switzerland, to focus on the development of new PDCs by combining our patented phospholipid ether delivery platform with Avicenna's novel cytotoxic warheads (potent anti-cancer small molecules). Those novel cytotoxic warheads were previously attempted to be made as antibody drug conjugates, and were unsuccessful.
Onconova Therapeutics is a publicly traded late stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Our collaboration focuses on taking two of their novel small molecule cancer drug candidates and looks to improve the pharmacologic behaviors of the molecules to improve the potential therapies. These molecules were not eligible to be turned into antibody drug conjugates.
University of Wisconsin-Madison
Our lead therapeutic compound, CLR 131, is currently in a Phase 2 clinical trial for multiple myeloma and select B-cell lymphomas as well as a Phase 1 dose escalation study in multiple myeloma. In collaboration with the University of Wisconsin, CLR 131 will be evaluated in combination with external beam radiation as a potential combination treatment for relapse/refractory head and neck cancers (squamous cell carcinoma). The research will be conducted as part of a Specialized Program of Research Excellence (SPORE) grant, awarded to the University of Wisconsin by the National Cancer Institute.
Additionally, we will be evaluating CLR 131 in a dose escalation study in select pediatric tumors. Specifically, in collaboration with the University of Wisconsin, we will evaluate CLR 131 as a treatment for neuroblastoma, high grade glioma, osteosarcoma, soft tissue sarcomas, and lymphomas.